The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis.

Mavis  Obeng-Kusi

No Relationships to Disclose

Daniel  Arku

No Relationships to Disclose

Neda  Alrawashdh

No Relationships to Disclose

Briana  Choi

No Relationships to Disclose

Nimer S.  Alkhatib

No Relationships to Disclose

Ali  McBride

Consulting or Advisory Role - EMD Serono; Pfizer; Sandoz

Speakers' Bureau - Bristol-Myers Squibb; Coherus Biosciences; Incyte

Ivo  Abraham

Stock and Other Ownership Interests  - Matrix45; Matrix45 (I)